Clinical TrialAug 5, 2026, 04:23 PM
Context Therapeutics CTIM-76 Phase 1a shows 29% ORR in PROC
AI Summary
Context Therapeutics Inc. updated its corporate presentation, highlighting positive interim Phase 1a clinical data for CTIM-76 in platinum-resistant ovarian cancer (PROC), showing a 29% overall response rate (ORR) and 57% disease control rate (DCR) in RECIST-evaluable patients. The company also received FDA Fast Track Designation for CTIM-76. Additionally, the presentation provided updates on CT-202, a Nectin-4 x CD3 bispecific antibody, with first patient in (FPI) expected in Q3 2026. The company anticipates cash runway into Q4 2027.
Key Highlights
- CTIM-76 Phase 1a interim data showed 29% overall response rate (ORR) in RECIST-evaluable platinum-resistant ovarian cancer (PROC) patients.
- CTIM-76 Phase 1a interim data showed 57% disease control rate (DCR) in RECIST-evaluable PROC patients.
- CTIM-76 received FDA Fast Track Designation for the treatment of platinum-resistant ovarian cancer.
- Initial Q3W dosing data for CTIM-76 Phase 1a is anticipated in Q2 2027.
- First Patient In (FPI) for CT-202 Phase 1a is expected in Q3 2026.
- Initial data for CT-202 Phase 1a is anticipated in 2H 2027.
- The company expects its cash runway to extend into Q4 2027.
Price Impact
More from CNTX